NO20006194D0 - Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri - Google Patents

Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri

Info

Publication number: NO20006194D0
Authority: NO; Norway
Prior art keywords: treatment; bowel syndrome; irritable bowel; functional dyspepsia; pharmaceutical composition
Prior art date: 1998-06-11

Application number

NO20006194A

Other languages

English (en)

Other versions

NO327738B1 (no

NO20006194L (no

Inventor

Per Hellstroem

Suad Efendic

Original Assignee

Per Hellstroem

Suad Efendic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-11

Filing date

2000-12-06

Publication date

2000-12-06

2000-12-06 Application filed by Per Hellstroem, Suad Efendic filed Critical Per Hellstroem

2000-12-06 Publication of NO20006194D0 publication Critical patent/NO20006194D0/no

2001-01-25 Publication of NO20006194L publication Critical patent/NO20006194L/no

2009-09-14 Publication of NO327738B1 publication Critical patent/NO327738B1/no

Links

201000006549 dyspepsia Diseases 0.000 title abstract 4
208000002551 irritable bowel syndrome Diseases 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
239000000126 substance Substances 0.000 title 1
230000001262 anti-secretory effect Effects 0.000 abstract 3
239000003626 gastrointestinal polypeptide Substances 0.000 abstract 3
210000001035 gastrointestinal tract Anatomy 0.000 abstract 3
239000005556 hormone Substances 0.000 abstract 3
229940088597 hormone Drugs 0.000 abstract 3
230000002586 relaxatory effect Effects 0.000 abstract 3
210000002460 smooth muscle Anatomy 0.000 abstract 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
239000000654 additive Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20006194A 1998-06-11 2000-12-06 Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning NO327738B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9802080A SE9802080D0 (sv)	1998-06-11	1998-06-11	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en)	1998-06-11	1999-06-08	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (3)

Publication Number	Publication Date
NO20006194D0 true NO20006194D0 (no)	2000-12-06
NO20006194L NO20006194L (no)	2001-01-25
NO327738B1 NO327738B1 (no)	2009-09-14

Family

ID=20411665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006194A NO327738B1 (no)	1998-06-11	2000-12-06	Anvendelse av et gastrointestinalt peptidhormon eller et derivat derav samt farmasoytisk sammensetning

Country Status (19)

Country	Link
US (1)	US6348447B1 (no)
EP (2)	EP1405642A1 (no)
JP (2)	JP2002517468A (no)
AT (1)	ATE252912T1 (no)
AU (1)	AU738994B2 (no)
CA (1)	CA2321700C (no)
CZ (1)	CZ300873B6 (no)
DE (1)	DE69912434T2 (no)
DK (1)	DK1094834T3 (no)
ES (1)	ES2205845T3 (no)
HU (1)	HUP0103147A3 (no)
NO (1)	NO327738B1 (no)
NZ (1)	NZ506163A (no)
PL (1)	PL198802B1 (no)
PT (1)	PT1094834E (no)
RU (1)	RU2226402C2 (no)
SE (1)	SE9802080D0 (no)
WO (1)	WO1999064060A1 (no)
ZA (1)	ZA200004080B (no)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001077137A1 (en)	2000-04-12	2001-10-18	Human Genome Sciences, Inc.	Albumin fusion proteins
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
ES2569916T3 (es)	1999-06-29	2016-05-13	Mannkind Corporation	Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
AU2001252201A1 (en)	2000-03-14	2001-09-24	Amylin Pharmaceuticals, Inc.	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
KR100518046B1 (ko)	2000-05-19	2005-10-04	아밀린 파마슈티칼스, 인크.	Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
EP2277889B1 (en)	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
JP4417113B2 (ja)	2002-02-20	2010-02-17	エミスフェアー・テクノロジーズ・インク	Ｇｌｐ−１分子の投与方法
ES2425392T3 (es)	2002-03-20	2013-10-15	Mannkind Corporation	Cartucho para un aparato de inhalación
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
ATE525395T1 (de)	2003-06-12	2011-10-15	Lilly Co Eli	Fusions proteine von glp-1-analoga
ES2338789T3 (es)	2003-06-18	2010-05-12	Tranzyme Pharma Inc.	Antagonistas macrociclicos del receptor de motilina.
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
ES2385934T3 (es)	2004-08-20	2012-08-03	Mannkind Corporation	Catálisis de la síntesis de dicetopiperazina.
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
EP1874339A1 (en) *	2005-04-21	2008-01-09	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
AU2006247734B2 (en)	2005-05-13	2011-06-23	Eli Lilly And Company	GLP-1 pegylated compounds
EP1904525A4 (en)	2005-06-30	2009-10-21	Ipsen Pharma	GLP-1 PHARMACEUTICAL COMPOSITIONS
JP4994374B2 (ja) *	2005-07-29	2012-08-08	ジオファームオンコロジー，インコーポレイテッド	がんを治療するための化合物および方法
US7799344B2 (en)	2005-09-14	2010-09-21	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US8039431B2 (en)	2006-02-22	2011-10-18	Mannkind Corporation	Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2009006942A (es) *	2006-12-29	2009-11-09	Ipsen Pharma Sas	Composiciones farmaceuticas de glp-1.
US8236760B2 (en) *	2007-04-27	2012-08-07	Cedars-Sinsai Medical Center	Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
BRPI0818874A2 (pt) *	2007-10-24	2015-05-05	Mannkind Corp	Liberação de agentes ativos
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
CA2703338A1 (en) *	2007-10-24	2009-04-30	Mannkind Corporation	Method of preventing adverse effects by glp-1
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
DK2293833T3 (en)	2008-06-13	2016-05-23	Mannkind Corp	DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
JP5604297B2 (ja)	2008-06-17	2014-10-08	株式会社糖鎖工学研究所	糖鎖付加ｇｌｐ−１ペプチド
JP5479465B2 (ja)	2008-06-20	2014-04-23	マンカインドコーポレイション	吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en)	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	GLP-1 analogues pharmaceutical compositions
CA2754595C (en)	2009-03-11	2017-06-27	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en)	2009-05-04	2013-12-24	Centocor Ortho Biotech Inc.	Fusion proteins of alpha-MSH derivatives and Fc
JP5751641B2 (ja)	2009-05-06	2015-07-22	ヤンセンバイオテツク，インコーポレーテツド	メラノコルチン受容体結合コンジュゲート
US8551528B2 (en)	2009-06-12	2013-10-08	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
NZ597777A (en) *	2009-07-29	2013-03-28	Daiichi Sankyo Co Ltd	Motilin-like peptide compound having transmucosal absorbability imparted thereto
EP2495255A4 (en)	2009-10-30	2013-05-15	Otsuka Chemical Co Ltd	GLYCOSYLATED FORM OF AN ANTIGENIC GLP-1 ANALOG
US9016147B2 (en)	2009-11-03	2015-04-28	Mannkind Corporation	Apparatus and method for simulating inhalation efforts
WO2011123943A1 (en) *	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
AU2011247452B2 (en)	2010-04-27	2016-03-17	Zealand Pharma A/S	Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
AU2011274229A1 (en)	2010-07-02	2013-01-10	Angiochem Inc.	Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
RS56998B1 (sr)	2010-12-16	2018-05-31	Novo Nordisk As	Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
MY180552A (en)	2011-04-01	2020-12-02	Mannkind Corp	Blister package for pharmaceutical cartridges
RU2602601C2 (ru)	2011-04-12	2016-11-20	Ново Нордиск А/С	Дважды ацилированные производные glp-1
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
EP2776053A1 (en)	2011-10-24	2014-09-17	MannKind Corporation	Methods and compositions for treating pain
MX2014005351A (es)	2011-11-03	2014-05-28	Zealand Pharma As	Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
TR201903918T4 (tr)	2012-03-22	2019-04-22	Novo Nordisk As	Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
WO2013139695A1 (en)	2012-03-22	2013-09-26	Novo Nordisk A/S	Compositions comprising a delivery agent and preparation thereof
CN104203266B (zh) *	2012-03-22	2017-12-26	诺和诺德股份有限公司	Glp‑1肽组合物及其制备
EP2863895B1 (en)	2012-06-20	2021-04-14	Novo Nordisk A/S	Tablet formulation comprising a peptide and a delivery agent
SG11201500218VA (en)	2012-07-12	2015-03-30	Mannkind Corp	Dry powder drug delivery systems and methods
IN2015DN00544A (no)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
RU2671406C2 (ru)	2013-05-02	2018-10-31	Ново Нордиск А/С	Пероральная дозированная форма соединений глюкагоноподобного пептида-1
MX394255B (es)	2013-07-18	2025-03-24	Mannkind Corp	Composiciones farmaceuticas en polvo seco estables al calor y metodos
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
CN104371019B (zh)	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
ES2688708T3 (es)	2013-10-17	2018-11-06	Zealand Pharma A/S	Análogos de glucagón acilados
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
EP3065767B1 (en)	2013-11-06	2020-12-30	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
US10131702B2 (en)	2013-11-06	2018-11-20	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US10253078B2 (en)	2014-10-29	2019-04-09	Zealand Pharma A/S	GIP agonist compounds and methods
KR101825048B1 (ko)	2014-12-31	2018-02-05	주식회사 제넥신	GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
CN105854000A (zh)	2015-02-11	2016-08-17	杭州鸿运华宁生物医药工程有限公司	一种药用glp-1r抗体融合蛋白的稳定溶液制剂
PL3283507T3 (pl)	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
SG11201903938XA (en)	2016-12-09	2019-05-30	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
BR112020014624A2 (pt)	2018-02-02	2020-12-08	Novo Nordisk A/S	Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
CN110305211A (zh)	2018-03-20	2019-10-08	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh)	2019-09-18	2021-03-19	鸿运华宁（杭州）生物医药有限公司	Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP4585617A1 (en)	2022-09-08	2025-07-16	Gmax Biopharm LLC	Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY147327A (en)	1995-06-29	2012-11-30	Novartis Ag	Somatostatin peptides
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides

1998
- 1998-06-11 SE SE9802080A patent/SE9802080D0/xx unknown
1999
- 1999-06-08 US US09/445,571 patent/US6348447B1/en not_active Expired - Lifetime
- 1999-06-08 ES ES99930089T patent/ES2205845T3/es not_active Expired - Lifetime
- 1999-06-08 AU AU46697/99A patent/AU738994B2/en not_active Ceased
- 1999-06-08 CA CA2321700A patent/CA2321700C/en not_active Expired - Fee Related
- 1999-06-08 DE DE69912434T patent/DE69912434T2/de not_active Expired - Lifetime
- 1999-06-08 NZ NZ506163A patent/NZ506163A/en unknown
- 1999-06-08 PL PL343104A patent/PL198802B1/pl not_active IP Right Cessation
- 1999-06-08 DK DK99930089T patent/DK1094834T3/da active
- 1999-06-08 RU RU2000133249/14A patent/RU2226402C2/ru not_active IP Right Cessation
- 1999-06-08 CZ CZ20004491A patent/CZ300873B6/cs not_active IP Right Cessation
- 1999-06-08 WO PCT/SE1999/000997 patent/WO1999064060A1/en not_active Ceased
- 1999-06-08 PT PT99930089T patent/PT1094834E/pt unknown
- 1999-06-08 AT AT99930089T patent/ATE252912T1/de not_active IP Right Cessation
- 1999-06-08 JP JP2000553128A patent/JP2002517468A/ja not_active Ceased
- 1999-06-08 HU HU0103147A patent/HUP0103147A3/hu unknown
- 1999-06-08 EP EP20030024624 patent/EP1405642A1/en not_active Withdrawn
- 1999-06-08 EP EP99930089A patent/EP1094834B1/en not_active Expired - Lifetime
2000
- 2000-08-10 ZA ZA200004080A patent/ZA200004080B/xx unknown
- 2000-12-06 NO NO20006194A patent/NO327738B1/no not_active IP Right Cessation
2010
- 2010-07-01 JP JP2010151403A patent/JP2010270125A/ja active Pending

Also Published As

Publication number	Publication date
DK1094834T3 (da)	2004-01-05
ZA200004080B (en)	2001-12-24
EP1094834B1 (en)	2003-10-29
AU4669799A (en)	1999-12-30
NO327738B1 (no)	2009-09-14
PT1094834E (pt)	2004-03-31
EP1405642A1 (en)	2004-04-07
AU738994B2 (en)	2001-10-04
DE69912434T2 (de)	2004-05-06
WO1999064060A1 (en)	1999-12-16
HUP0103147A2 (hu)	2002-01-28
JP2010270125A (ja)	2010-12-02
CA2321700A1 (en)	1999-12-16
ATE252912T1 (de)	2003-11-15
US6348447B1 (en)	2002-02-19
DE69912434D1 (de)	2003-12-04
ES2205845T3 (es)	2004-05-01
PL343104A1 (en)	2001-07-30
CZ300873B6 (cs)	2009-09-02
EP1094834A1 (en)	2001-05-02
NZ506163A (en)	2004-10-29
RU2226402C2 (ru)	2004-04-10
PL198802B1 (pl)	2008-07-31
CZ20004491A3 (en)	2001-05-16
CA2321700C (en)	2011-05-03
NO20006194L (no)	2001-01-25
HUP0103147A3 (en)	2002-02-28
SE9802080D0 (sv)	1998-06-11
JP2002517468A (ja)	2002-06-18

Publication	Publication Date	Title
NO20006194L (no)	2001-01-25	Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
RU2000133249A (ru)	2002-11-27	Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
NO984005L (no)	1998-08-31	Anvendelse av et farmas°ytisk preparat som omfatter et appetittundertrykkende peptid
FI954941A7 (fi)	1996-04-19	Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
BR0212080A (pt)	2006-04-04	composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
KR950002785A (ko)	1995-02-16	골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE316100T1 (de)	2006-02-15	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO2001068112A3 (en)	2002-03-07	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
NZ334270A (en)	2000-07-28	Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
EA200300026A1 (ru)	2003-04-24	Аналоги глюкагоноподобного пептида-1
EP1992641A3 (en)	2009-07-29	GLP-1 analogues
NO20041203L (no)	2004-06-10	Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
ATE182078T1 (de)	1999-07-15	Laxiermittel das ballastfasern und dioctyl- sulfosuccinat enthält
FI943028A7 (fi)	1994-06-22	Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiint yvien, haavaumia aiheuttavien sairauksien hoitamiseksi
IS1966B (is)	2004-12-15	Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
DE69011618D1 (de)	1994-09-22	Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
AU3733295A (en)	1996-05-02	Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
WO2003092619A3 (en)	2004-10-07	Prevention and treatment of type 2 diabetes
SE8501203D0 (sv)	1985-03-11	Mammal intestinal hormone precursor and its use
DE60002143D1 (de)	2003-05-22	Behandlung autoimmunerkrankungen in säugern
马连生 et al.	1994	COMBINATION OF TRADITIONAL CHINESE MEDICINE AND WESTERN MEDICINE IN THE TREATMENT OF RESISTANT PEPTIC ULCER
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos
RU93032468A (ru)	1996-04-10	Способ лечения мышечно-тонического и нейро-дистрофического синдрома шейного и грудного остеохондроза

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees